MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2022 International Congress

    Real-world evidence and feasibility of telemedicine for Parkinson’s disease

    G. Rigas, N. Kostikis, N. Tachos, E. Kontogiannis, E. Kostoulas, A. Bousis, S. Konitsiotis, D. Fotiadis (Ioannina, Greece)

    Objective: This work aims to provide real-world evidence for the feasibility of telemedicine in Parkinson’s disease (PD). Adherence data presented pertain to patients paying out…
  • 2022 International Congress

    Changes in gait and mobility measures collected in daily living conditions, in different stages of Parkinson’s disease

    N. Geffen, K. Cohavi, N. Giladi, A. Thaler, R. Alcalay, J. Edgerton, J. Shirvan, J. Cedarbaum, J. Hausdorff, A. Mirelman (Tel Aviv, Israel)

    Objective: To explore mobility measures collected in daily-living conditions in different stages of PD. Background: Gait and mobility impairments are considered a cardinal sign in…
  • 2022 International Congress

    IMPACT OF DEEP BRAIN STIMULATION ELECTRODE POSITION ON GAIT IN PATIENTS WITH PARKINSON’S DISEASE

    J. Bardoň, D. Burďáková, J. Valošek, D. Krahulík, P. Otruba, P. Kaňovský, M. Nevrlý (Olomouc, Czech Republic)

    Objective: The aim of our study is to evaluate the impact of the deep brain stimulation (DBS) electrode position within the subthalamic nucleus on gait…
  • 2022 International Congress

    Plasma biomarkers of disease progression in Parkinson’s disease

    A. Lupini, N. Ashton, A. Pilotto, B. Battaglio, C. Zatti, S. Gipponi, E. Cottini, I. Grossi, A. Salvi, G. de Petro, M. Pizzi, K. Blennow, H. Zetterberg, A. Padovani (Brescia, Italy)

    Objective: To identify the ability of a panel of plasma biomarkers to predict disease progression in PD patients Background: Plasma neurofilament light chain (NfL) has…
  • 2022 International Congress

    Blood neurofilament light chain as a biomarker of Parkinson’s disease

    S. Ganesh, B. Huxford, A. Zirra, C. Edwards, C. Simonet, T. Haque, D. Gallagher, C. Budu, R. Dobson, A. Noyce (London, United Kingdom)

    Objective: The objective of the study was to analyse blood neurofilament light chain (NfL) levels in patients with Parkinson’s disease (PD) and healthy controls (HCs),…
  • 2022 International Congress

    Initial Postmarketing Real World Experience with directSTIM™ DBS System: A Case Series

    W. Polanski, S. Sobottka, V. Coenen, A. Frank, B. Falkenburger (Dresden, Germany)

    Objective: In this study we report the first three cases of a new, CE-marked system for deep brain stimulation. Background: The PMCF study is a…
  • 2022 International Congress

    Impact of foslevodopa/foscarbidopa on key clinical and patient-reported outcomes in patients with aPD: Responder analysis of two Phase 3 clinical trials

    M. Soileau, J. Aldred, A. Antonini, C. Carroll, V. Fung, T. Henriksen, R. Pahwa, D. Santos Garcia, A. Epstein, C. Yan, A. Alobaidi, A. Shewale, A. Spiegel, M. Facheris, J. Zamudio, P. Kukreja, KR. Chaudhuri (Georgetown, USA)

    Objective: To evaluate the effect of foslevodopa/foscarbidopa (LDP/CDP, ABBV-951) on clinical and patient-reported outcomes in advanced Parkinson’s disease (aPD) patients using minimal clinically important difference…
  • 2022 International Congress

    Monogenic Hub of the Global Parkinson’s Genetics Program (GP2): In search of new PD genes

    L. Lange, ZH. Fang, E. Valente, SY. Lim, A. Tan, A. Illarionova, M. Avenali, I. Keller Sarmiento, H. Madoev, K. Roopnarain, C. Galandra, M. Ellis, K. Kumar, P. Heutink, N. Mencacci, K. Lohmann, C. Klein (Lübeck, Germany)

    Objective: To identify novel monogenic causes of Parkinson’s disease (PD) by performing short and long-read sequencing for up to 10,000 PD patients and families with…
  • 2022 International Congress

    Heart rate variability is affected by standing and medication intake in Parkinson’s disease

    F. Cucinotta, F. Morgante, I. Cociasu, E. Pereira, E. Makovac, L. Ricciardi (London, United Kingdom)

    Objective: To evaluate the effect of levodopa and orthostatism on heart rate variability (HRV) in a sample of consecutive subjects with Parkinson's disease (PD). Background:…
  • 2022 International Congress

    Olfactory Network Reorganization in Parkinson’s Disease

    L. Pesantez Pacheco, M. Saqib, D. Ehrlich, M. Hallett, S. Horovitz (Bethesda, USA)

    Objective: To explore changes in the organization and functionality of the olfactory network in patients with Parkinson’s Disease (PD) using graph theory-based network analysis on…
  • « Previous Page
  • 1
  • …
  • 317
  • 318
  • 319
  • 320
  • 321
  • …
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley